전체메뉴
검색
Article Search

JMB Journal of Microbiolog and Biotechnology

QR Code QR Code

Note

Clinical Microbiology and Biomedical Sciences

A Double-Blind, Placebo Controlled-Trial of a Probiotic Strain Lactobacillus sakei Probio-65 for the Prevention of Canine Atopic Dermatitis

Hyejin Kim 1, Irfan A. Rather 2, Hyunwook Kim 1, Sungsoo Kim 1, Taeeun Kim 1, Jaeyoung Jang 1, Jimin Seo 1, Jeongheui Lim 3 and Yong-Ha Park 2, 4*

1Haemaru Referral Animal Hospital, Sungnam 463-050, Republic of Korea, 2Department of Applied Microbiology and Biotechnology, Yeungnam University, Gyeongsan 712-749, Republic of Korea, 3National Science Museum Ministry of Science, ICT and Future Planning, Daejeon 305-705, Republic of Korea, 4proBionic, Yusung, Daejeon 305-333, Republic of Korea

Received: June 29, 2015; Accepted: August 11, 2015

J. Microbiol. Biotechnol. 2015; 25(11): 1966-1969

Published November 28, 2015 https://doi.org/10.4014/jmb.1506.06065

Copyright © The Korean Society for Microbiology and Biotechnology.

Abstract

Canine atopic dermatitis (CAD) is a ubiquitous, chronic inflammatory skin disorder prevalent in dogs, which results in production of abnormal levels of IgE antibodies in reciprocation to an allergen challenge. In this study, administration of the probiotic strain Lactobacillus sakei probio-65 for 2 months significantly reduced the disease severity index in experimental dogs diagnosed with CAD. In addition, one month pre-medication of L. sakei probio-65 revealed significant difference in the PVAS score in experimental dogs for both probio-65 and placebo groups. However, post 2 months treatment resulted in a significant decrease in the CASESI score values in the probio-65-treated group (p < .0.06).

Keywords

Canine atopic dermatitis, Lactobacillus sakei, probiotics, skin disorder

Related articles in JMB

More Related Articles

Article

Note

J. Microbiol. Biotechnol. 2015; 25(11): 1966-1969

Published online November 28, 2015 https://doi.org/10.4014/jmb.1506.06065

Copyright © The Korean Society for Microbiology and Biotechnology.

A Double-Blind, Placebo Controlled-Trial of a Probiotic Strain Lactobacillus sakei Probio-65 for the Prevention of Canine Atopic Dermatitis

Hyejin Kim 1, Irfan A. Rather 2, Hyunwook Kim 1, Sungsoo Kim 1, Taeeun Kim 1, Jaeyoung Jang 1, Jimin Seo 1, Jeongheui Lim 3 and Yong-Ha Park 2, 4*

1Haemaru Referral Animal Hospital, Sungnam 463-050, Republic of Korea, 2Department of Applied Microbiology and Biotechnology, Yeungnam University, Gyeongsan 712-749, Republic of Korea, 3National Science Museum Ministry of Science, ICT and Future Planning, Daejeon 305-705, Republic of Korea, 4proBionic, Yusung, Daejeon 305-333, Republic of Korea

Received: June 29, 2015; Accepted: August 11, 2015

Abstract

Canine atopic dermatitis (CAD) is a ubiquitous, chronic inflammatory skin disorder prevalent
in dogs, which results in production of abnormal levels of IgE antibodies in reciprocation to an
allergen challenge. In this study, administration of the probiotic strain Lactobacillus sakei
probio-65 for 2 months significantly reduced the disease severity index in experimental dogs
diagnosed with CAD. In addition, one month pre-medication of L. sakei probio-65 revealed
significant difference in the PVAS score in experimental dogs for both probio-65 and placebo
groups. However, post 2 months treatment resulted in a significant decrease in the CASESI
score values in the probio-65-treated group (p < .0.06).

Keywords: Canine atopic dermatitis, Lactobacillus sakei, probiotics, skin disorder